Trevi Therapeutics

OverviewSuggest Edit

Trevi Therapeutics is a drug development company focused on developing Nalbuphine ER for the severe chronic itching condition known as pruritus. 

TypePublic
Founded2011
HQNew Haven, CT, US
Websitetrevitherapeutics.com

Latest Updates

Employees (est.) (Mar 2020)19(+12%)
Revenue (FY, 2018)$14.1 M(+131%)
Share Price (Apr 2021)$2.4(+3%)
Cybersecurity ratingBMore

Key People/Management at Trevi Therapeutics

Jennifer Good

Jennifer Good

Co-Founder, President and CEO, Director
Thomas Sciascia

Thomas Sciascia

Co-Founder, Chief Medical Officer
Helena Brett-Smith

Helena Brett-Smith

Chief Development Officer
William Forbes

William Forbes

Chief Development Officer
David Meeker

David Meeker

Chairman
Show more

Trevi Therapeutics Office Locations

Trevi Therapeutics has an office in New Haven
New Haven, CT, US (HQ)
195 Church St
Show all (1)

Trevi Therapeutics Financials and Metrics

Trevi Therapeutics Revenue

Trevi Therapeutics's revenue was reported to be $14.07 m in FY, 2018 which is a 130.9% increase from the previous period.
USD

Net income (FY, 2020)

(32.8m)

EBIT (FY, 2020)

(32.5m)

Market capitalization (26-Apr-2021)

48.0m

Closing stock price (26-Apr-2021)

2.4

Cash (31-Dec-2020)

45.0m

EV

17.5m
Trevi Therapeutics's current market capitalization is $48 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

6.1m14.1m

Revenue growth, %

131%

General and administrative expense

2.1m4.3m7.3m10.2m

R&D expense

6.1m14.1m19.3m22.3m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

1.5m1.9m2.0m2.6m2.5m

R&D expense

3.3m5.5m5.7m6.0m4.9m

Operating expense total

4.8m7.4m7.7m8.6m7.4m

EBIT

(4.8m)(7.4m)(7.6m)(8.6m)(7.4m)
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

22.0m7.2m57.3m45.0m

Prepaid Expenses

93.0k1.4m1.7m1.0m

Current Assets

22.2m8.8m59.6m46.3m

PP&E

14.0k149.0k118.0k103.0k
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

12.9m71.4m63.5m52.6m44.2m

Prepaid Expenses

1.7m3.0m1.8m1.1m2.1m

Current Assets

14.8m74.6m65.5m53.8m46.3m

PP&E

149.0k139.0k128.0k107.0k109.0k
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(12.9m)(20.5m)(26.0m)(32.8m)

Depreciation and Amortization

4.0k23.0k39.0k47.0k

Accounts Payable

92.0k66.0k777.0k417.0k

Cash From Operating Activities

(8.0m)(18.3m)(23.1m)(29.0m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(4.8m)(12.1m)(19.5m)(8.5m)(15.9m)

Depreciation and Amortization

9.0k19.0k30.0k10.0k21.0k

Accounts Payable

(185.0k)1.7m(332.0k)594.0k1.6m

Cash From Operating Activities

(4.1m)(9.2m)(16.9m)(4.7m)(13.1m)
USDFY, 2017

Revenue/Employee

746.3k

Debt/Equity

-0.1 x

Debt/Assets

0.2 x

Financial Leverage

-0.3 x
Show all financial metrics

Trevi Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Trevi Therapeutics Limited

Trevi Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Trevi Therapeutics Online and Social Media Presence

Embed Graph

Trevi Therapeutics News and Updates

Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

NEW HAVEN, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management…

Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25

Conference Call and Webcast to be Held at 4:30 p.m. ET Conference Call and Webcast to be Held at 4:30 p.m. ET

Trevi Therapeutics Appoints William Forbes, Pharm.D. as Chief Development Officer

Industry Veteran to Lead the Clinical Development of Haduvio™ in Multiple Indications

Trevi Therapeutics to Present at Stifel Healthcare Conference

NEW HAVEN, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management …

Trevi Therapeutics to Report Q3 2020 Financial Results on November 11

Conference Call and Webcast to be Held at 4:30 p.m. ET Conference Call and Webcast to be Held at 4:30 p.m. ET

Trevi Therapeutics Provides Clinical Trial Updates for Haduvio™

Restart of Phase 2 Clinical Trial of Haduvio for Chronic Cough in Patients with IPF
Show more

Trevi Therapeutics Frequently Asked Questions

  • When was Trevi Therapeutics founded?

    Trevi Therapeutics was founded in 2011.

  • Who are Trevi Therapeutics key executives?

    Trevi Therapeutics's key executives are Jennifer Good, Thomas Sciascia and Helena Brett-Smith.

  • How many employees does Trevi Therapeutics have?

    Trevi Therapeutics has 19 employees.

  • Who are Trevi Therapeutics competitors?

    Competitors of Trevi Therapeutics include Cassava Sciences, Chiesi USA and R-Pharm.

  • Where is Trevi Therapeutics headquarters?

    Trevi Therapeutics headquarters is located at 195 Church St, New Haven.

  • Where are Trevi Therapeutics offices?

    Trevi Therapeutics has an office in New Haven.

  • How many offices does Trevi Therapeutics have?

    Trevi Therapeutics has 1 office.